Mankyu Park
Direktor/Vorstandsmitglied bei Coagulant Therapeutics, Inc.
Aktive Positionen von Mankyu Park
| Unternehmen | Position | Beginn | Ende |
|---|---|---|---|
Coagulant Therapeutics, Inc.
 Coagulant Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Coagulant Therapeutics, Inc. is a privately held company that focuses on designing, developing, and commercializing therapeutics for the coagulation cascade and its adjacencies. Coagulant Therapeutics is based in Berkeley, CA. The company's lead product candidate, CT-001, is a next-generation Factor VIIa designed for enhanced efficacy and safety in the setting of acute bleeding. The company is also developing additional therapeutics targeted to APC for the treatment of acute bleeding and other coagulation cascade-related diseases. The company was founded in 2019 by Terry Hermiston, who has been the CEO since then. | Direktor/Vorstandsmitglied | - | - |
Karriereverlauf von Mankyu Park
Ehemalige bekannte Positionen von Mankyu Park
| Unternehmen | Position | Beginn | Ende |
|---|---|---|---|
| DTCP Management GmbH | Corporate Officer/Principal | - | - |
Ausbildung von Mankyu Park
| Goizueta Business School-Emory | Undergraduate Degree |
Statistik
International
| Vereinigte Staaten | 3 |
| Südkorea | 2 |
Operativ
| Director/Board Member | 1 |
| Corporate Officer/Principal | 1 |
| Undergraduate Degree | 1 |
Sektoral
| Consumer Services | 2 |
| Finance | 2 |
| Health Technology | 2 |
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Unternehmensverbindungen
| Private Unternehmen | 2 |
|---|---|
| DTCP Management GmbH | Finance |
Coagulant Therapeutics, Inc.
Coagulant Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Coagulant Therapeutics, Inc. is a privately held company that focuses on designing, developing, and commercializing therapeutics for the coagulation cascade and its adjacencies. Coagulant Therapeutics is based in Berkeley, CA. The company's lead product candidate, CT-001, is a next-generation Factor VIIa designed for enhanced efficacy and safety in the setting of acute bleeding. The company is also developing additional therapeutics targeted to APC for the treatment of acute bleeding and other coagulation cascade-related diseases. The company was founded in 2019 by Terry Hermiston, who has been the CEO since then. | Health Technology |
- Börse
- Insiders
- Mankyu Park
- Erfahrung
